Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202105469
Abstract: Targeting the G2/M checkpoint mediator WEE1 has been explored as a novel treatment strategy in ovarian cancer, but mechanisms underlying its efficacy and resistance remains to be understood. Here, it is demonstrated that the WEE1… read more here.
Keywords: tp53 mutant; unfolded protein; ovarian cancer; protein response ... See more keywords
Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-1124
Abstract: DNA repair pathway inhibitors are a new class of anti-cancer drugs that are advancing in clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is a key driver of non-homologous end-joining (NHEJ).… read more here.
Keywords: dna repair; tp53 mutant; dna; synthetic lethality ... See more keywords
Abstract 787: Cytosolic TRIM24 characterizes an aggressive subset of ER- PR- and TP53 mutant breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-787
Abstract: Introduction: Tripartite Motif Containing 24 (TRIM24) is a PhD/Bromodomain containing steroid receptor co-activator that targets p53 for proteosomal degradation, transforms human mammary epithelial cells, and promotes treatment resistance in preclinical models. While bromodomain inhibitors and… read more here.
Keywords: trim24; breast cancer; cancer; tp53 mutant ... See more keywords
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2020006158
Abstract: Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise… read more here.
Keywords: myelodysplastic syndromes; secondary aml; tp53 mutant; tp53 mutations ... See more keywords
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003300
Abstract: Mature natural killer (NK) cell neoplasms are rare but very aggressive types of cancers. With currently available treatments, they have a very poor prognosis and, as such, are an example of group of cancers in… read more here.
Keywords: cell neoplasms; inhibitor; drug; tp53 mutant ... See more keywords
TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006580
Abstract: A recent article in Blood Advances by Short et al 1 entitled “ Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia, ” had very interesting conclusions that… read more here.
Keywords: tp53 mutant; acute myeloid; myeloid leukemia; hematology ... See more keywords
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00181
Abstract: PURPOSE Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. PATIENTS AND METHODS We conducted… read more here.
Keywords: tp53 mutant; myeloid leukemia; allogeneic hematopoietic; myelodysplastic syndromes ... See more keywords
Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)
Sign Up to like & getrecommendations! Published in 2023 at "Oncotarget"
DOI: 10.18632/oncotarget.28355
Abstract: TP53 mutant head and neck squamous cell carcinoma (HNSCC) patients exhibit poor clinical outcomes with 50–60% recurrence rates in advanced stage patients. In a recent phase II clinical trial, adjuvant therapy with everolimus (mTOR inhibitor)… read more here.
Keywords: tp53 mutant; cell; hif; hif vegf ... See more keywords
Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1035616
Abstract: Objective Tumor immune microenvironmental features may predict survival and guide treatment. This study aimed to comprehensively decipher the immunological features of different molecular subtypes of endometrial cancer. Methods In this retrospective study, 26 patients with… read more here.
Keywords: endometrial cancer; tumor; study; tp53 mutant ... See more keywords
A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Surgery"
DOI: 10.3389/fsurg.2023.1079129
Abstract: Background TP53 is one of the most frequent mutated genes in colon cancer. Although colon cancer with TP53 mutations has a high risk of metastasis and worse prognosis generally, it showed high heterogeneity clinically. Methods… read more here.
Keywords: tp53 mutant; prognosis; tp53 mutations; coad ... See more keywords
TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers15010029
Abstract: Simple Summary Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene TP53 is rapidly lethal for most patients. Here, we investigated the preclinical activity of TP-0903, a multikinase inhibitor that inhibits kinases with… read more here.
Keywords: tp53 mutant; cell; mutant aml; aml ... See more keywords